David Dai
Stock Analyst at Bernstein
(2.24)
# 2,774
Out of 5,245 analysts
42
Total ratings
45.71%
Success rate
-1.43%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARM Arm Holdings | Initiates: Outperform | $300 | $306.51 | -2.12% | 1 | May 18, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $38 → $37 | $19.94 | +85.56% | 4 | May 13, 2026 | |
| JANX Janux Therapeutics | Downgrades: Neutral | $57 → $15 | $14.52 | +3.31% | 2 | Apr 15, 2026 | |
| ASML ASML Holding | Maintains: Outperform | $1,911 → $1,971 | $1,632.90 | +20.71% | 3 | Mar 26, 2026 | |
| JSPR Jasper Therapeutics | Assumes: Neutral | $1.5 | $0.903 | +66.11% | 1 | Mar 23, 2026 | |
| CATX Perspective Therapeutics | Maintains: Buy | $7 → $8 | $3.98 | +101.01% | 3 | Mar 18, 2026 | |
| SONY Sony Group | Downgrades: Market Perform | $30 → $22 | $22.14 | -0.63% | 2 | Mar 17, 2026 | |
| KURA Kura Oncology | Maintains: Buy | $16 → $15 | $11.25 | +33.33% | 4 | Mar 13, 2026 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $2 → $4 | $4.11 | -2.68% | 3 | Mar 5, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $90 → $128 | $78.89 | +62.25% | 1 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $115 → $117 | $92.14 | +26.98% | 1 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $114 → $132 | $102.12 | +29.26% | 3 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $20 | $9.47 | +111.19% | 1 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $26 | $17.50 | +48.57% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $16.62 | +80.51% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $24 | $13.84 | +73.41% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $28.83 | -16.75% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $29.10 | +71.82% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $64.13 | -6.44% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $448 | $8.30 | +5,297.59% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $101.32 | -60.52% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $4.53 | +783.00% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $3.03 | +1,550.17% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $30.52 | +70.38% | 1 | Mar 17, 2020 |
Arm Holdings
May 18, 2026
Initiates: Outperform
Price Target: $300
Current: $306.51
Upside: -2.12%
Syndax Pharmaceuticals
May 13, 2026
Maintains: Buy
Price Target: $38 → $37
Current: $19.94
Upside: +85.56%
Janux Therapeutics
Apr 15, 2026
Downgrades: Neutral
Price Target: $57 → $15
Current: $14.52
Upside: +3.31%
ASML Holding
Mar 26, 2026
Maintains: Outperform
Price Target: $1,911 → $1,971
Current: $1,632.90
Upside: +20.71%
Jasper Therapeutics
Mar 23, 2026
Assumes: Neutral
Price Target: $1.5
Current: $0.903
Upside: +66.11%
Perspective Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $7 → $8
Current: $3.98
Upside: +101.01%
Sony Group
Mar 17, 2026
Downgrades: Market Perform
Price Target: $30 → $22
Current: $22.14
Upside: -0.63%
Kura Oncology
Mar 13, 2026
Maintains: Buy
Price Target: $16 → $15
Current: $11.25
Upside: +33.33%
Iovance Biotherapeutics
Mar 5, 2026
Maintains: Neutral
Price Target: $2 → $4
Current: $4.11
Upside: -2.68%
Kymera Therapeutics
Mar 3, 2026
Maintains: Buy
Price Target: $90 → $128
Current: $78.89
Upside: +62.25%
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $92.14
Upside: +26.98%
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $102.12
Upside: +29.26%
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $9.47
Upside: +111.19%
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $17.50
Upside: +48.57%
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $16.62
Upside: +80.51%
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $13.84
Upside: +73.41%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $28.83
Upside: -16.75%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $29.10
Upside: +71.82%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $64.13
Upside: -6.44%
Mar 31, 2022
Initiates: Outperform
Price Target: $448
Current: $8.30
Upside: +5,297.59%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $101.32
Upside: -60.52%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $4.53
Upside: +783.00%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $3.03
Upside: +1,550.17%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $30.52
Upside: +70.38%